UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017571
Receipt number R000020360
Scientific Title The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer
Date of disclosure of the study information 2015/05/14
Last modified on 2015/05/14 20:29:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

Acronym

The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

Scientific Title

The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

Scientific Title:Acronym

The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

Region

Japan


Condition

Condition

Breast Cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To clarify the effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

BMD change from baseline to 5 years at the lumbar spine and femoral neck

Key secondary outcomes

BMD change from baseline to 6, 12, 24, 36, 48 and 50 months at the lumbar spine and femoral neck
Bone fracture rate during 5 years


Base

Study type


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Initiaion of bisphosphonate (risedronate or alendronate) when patients were diagnosed with osteoporosis having a T-score of -2.5 or lower.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Primary breast cancer in stage 0 to IIIC
Treatment with anastrozole
Postmenopausal E2 <30pg/ml
Written informed concent

Key exclusion criteria

Patients already treated as osteoporosis

Target sample size

55


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tadao Shimizu

Organization

Tokyo Women's Medical University Medical Center East

Division name

Department of Breast Surgery

Zip code


Address

2-1-10 Nishiogu, Arakawa-ku, Tokyo 116-8567, Japan

TEL

03-3810-1111

Email

shimitsu@dnh.twmu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akira Hirano

Organization

Tokyo Women's Medical University Medical Center East

Division name

Department of Breast Surgery

Zip code


Address

2-1-10 Nishiogu, Arakawa-ku, Tokyo 116-8567, Japan

TEL

03-3810-1111

Homepage URL


Email

ahirasu@dnh.twmu.ac.jp


Sponsor or person

Institute

Tokyo Women's Medical University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 05 Month 14 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2004 Year 07 Month 26 Day

Last follow-up date

2015 Year 04 Month 01 Day

Date of closure to data entry

2015 Year 04 Month 01 Day

Date trial data considered complete

2015 Year 05 Month 14 Day

Date analysis concluded

2015 Year 05 Month 14 Day


Other

Other related information



Management information

Registered date

2015 Year 05 Month 14 Day

Last modified on

2015 Year 05 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020360


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name